# Lys Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lys-therapeutics

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.lystherapeutics.com
- Total disclosed funding: $3.1M
- Latest round: Seed (Nov 14, 2022)
- Investors on record: 1

## About

Lys Therapeutics SAS, based in France, develops innovative biotherapies targeting neurological diseases, focusing on restoring blood-brain barrier integrity through advanced monoclonal antibody treatments. Founded in 2021 by CEO Manuel Blanc, CFO Philippe Dujardin and Thibault Honegger, headquartered in Lyon, France, Lys Therapeutics SAS is dedicated to developing therapies for neurological disorders. In September 2025, the company has successfully secured funding through a GRANT of USD 5.00 mn from Bpifrance, Normandie Participations, France 2030 and Michael J. Fox Foundation, which will support its ongoing projects. Lys Therapeutics has executed a total of 3 deals since its inception, focusing primarily on advancing its flagship product. Lys Therapeutics specializes in innovative biotherapies for neurological conditions, with its lead product LYS241 being a first-in-class monoclonal antibody. LYS241 aims to mitigate neuroinflammation and neurodegeneration by inhibiting the binding of tissue plasminogen activator to NMDA receptors, preserving their function and halting neurotoxic pathways. The company’s focus is on Western European and North American markets, collaborating with healthcare providers and research institutions to ensure effective patient care. Lys Therapeutics generates revenue through strategic partnerships and grants aimed at advancing LYS241 through clinical development. Collaborations with research institutions, pharmaceutical companies, and organizations such as The Michael J. Fox Foundation are integral to their financial model, which includes funding agreements and research partnerships that contribute to the development of their therapeutic pipeline. Lys Therapeutics plans to utilize its June 2026 GRANT funding to complete regulatory studies, enhance manufacturing readiness, and advance its neurological disease therapy program into clinical development. The company aims to introduce new products and expand its reach into additional markets as it continues to develop innovative treatments for neurological disorders.

## Funding rounds

- Seed, Nov 14, 2022, $3.1M — Health Technology Holding

## Investors

- Health Technology Holding (https://capitalatlas.ai/funds/health-technology-holding) — Seed